Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Jeffrey Gelfand
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
EnBioTix
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
EnBioTix is developing a treatment for catheter-associated urinary tract infections. The goal of the NIH grant is to develop a new approach to treating urinary tract infections without the use of antibiotics. The results of the research grant could potentially affect the interests of EnBioTix. Based on the magnitude of this financial interest and the close connection between the company's interests and the research, the review panel determined that the financial interest could directly and significantly affect the design, conduct, or reporting of the research.
Synergistic Photodynamic Therapy for Catherer-Associated Urinary Tract Infections
Over a million cases of urinary tract infections are diagnosed each year in people who use urinary catheters for medical purposes, and the repeated use of antibiotics to treat these infections contributes to the spread of antibiotic-resistant bacteria. Tis project addresses U.S. public health by investigating a different method of killing bacteria and treating bladder infections that does not use antibiotics and does not contribute to the further development of antibiotic resistance.
Filed on December 02, 2015.
Tell us what you know about Jeffrey Gelfand's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Jeffrey Gelfand”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Jeffrey Gelfand | University of California, San Francisco | Financial Disclosure | Genentech, Inc. |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.